Results 131 to 140 of about 187,608 (218)

Immunoinformatic insights for design and clinical prospects of pan-RAS cancer vaccine. [PDF]

Front Med (Lausanne)
Srivastava R, Rana TRK.
europepmc   +1 more source

Regulatory harmonization: Evolution, globalization and future directions

British Journal of Clinical Pharmacology, EarlyView.
Regulatory harmonization has become an increasingly important and accepted approach to streamline regulatory review processes and expedite access to safe, effective and high‐quality medicines globally. This review explores the evolution and current status of regulatory harmonization, convergence and reliance initiatives.
Orin Chisholm, Elaine Y. L. Blair, Christine Y. Lu   +2 more
wiley   +1 more source

Cancer Vaccine Targeting Mutated GNAQ-Expressing Uveal Melanoma. [PDF]

Cancers (Basel)
Alexeev V, Terai M, Koshkin S, Igoucheva O, Sato T.   +4 more
europepmc   +1 more source

Extracellular Vesicles‐Based Biological Macromolecule Delivery Systems: Biogenesis, Characterization, and Emerging Clinical Applications

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are nanoscale membrane‐bound structures that play a pivotal role in intercellular communication by transporting bioactive molecules, including proteins, lipids, nucleic acids, and organelles, between cells. Originating from the endosomal pathway, EVs reflect the physiological and pathological status of their parent
Emine İncilay Torunoğlu, Zeynep Betül Sarı, Muhammed Emin Sarı, Erdi Can Aytar   +3 more
wiley   +1 more source

Purification of Disassembled Capsid Protein by Hydroxyapatite Chromatography Enhances Virus‐Like Particle Recovery

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Virus‐like particles (VLPs) are a promising modality with extensive applications in prophylactic and therapeutic vaccine design. Human Papillomavirus (HPV) vaccines are one such example where VLP vaccine applications have led to the successful reduction in HPV‐associated diseases, such as cervical cancer.
Nicholas Samuelson, Nathaniel Parker, Shiyi Wang, Sara Daley, Aaron Cote, Michael A. Winters   +5 more
wiley   +1 more source

Targeting Telomerase in Cancer: Vaccine-Based Strategies, Clinical Evidence, and Synergy with Immunotherapy. [PDF]

Diseases
Baliou S, Tzatzarakis MN, Tsantes AG, Vakonaki E, Ioannou P, Kyriakakis M, Hatzidaki E, Pelagiadis I, Stiakaki E, Tsatsakis A.   +9 more
europepmc   +1 more source

Mechanistic Digital Model for Real‐Time Monitoring and Optimization of Adenovirus Production

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Adenoviral vectors are a critical vaccine platform, with billions of vaccine doses administered during the COVID‐19 pandemic. In addition, they are promising therapeutics for cancer treatment. To advance their manufacturing, real‐time monitoring of adenovirus production is essential for process optimization, yield improvement, and product ...
Xingge Xu, Daniel Rüdiger, Jeongbin Shin, Shawninder Chahal, Amine Kamen   +4 more
wiley   +1 more source

Converting focused ultrasound-based boiling histotripsy into a systemic cancer vaccine using antigen-capturing microparticles. [PDF]

Theranostics
Singh A, Chandrasekar SV, Chamani F, Ashar H, Hartson S, Fiering S, Ranjan A.   +6 more
europepmc   +1 more source

Cryo‐EM Analysis of Adenovirus Vector Reveals Purification Conditions Leading to Loss of Viral Fiber Proteins and Reduced Infectivity

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Vaccines and gene therapies require efficient delivery of genetic material to host cells. Viral vectors leverage viruses' ability to enter host cells to achieve this. Following the SARS‐CoV‐2 vaccine and novel gene therapies that utilize adenovirus vectors, there has been an increase in the demand for large‐scale production of vectors.
Betsy Widdicombe, Joseph D. Barritt, Nichakorn Pipatpadungsin, Braulio Carrillo Sanchez, Dale Stibbs, Lisa Cooper, Sarah L. Rouse, Daniel G. Bracewell   +7 more
wiley   +1 more source

Novel lipid nanoparticle in a mRNA cancer vaccine drives tumor control via type I IFNs and effector CD8⁺ T cells. [PDF]

Mol Ther Nucleic Acids
Gold MJ, Millar DG, Liu J, Menon H, Karpov Y, Olsen K, Oliveira LT, Dubé C, Tran CW, Elford AR, Schwartz JA, Gopalakrishna Panicker RK, Marcusson EG, Ohashi PS, Martin Orozco N.   +14 more
europepmc   +1 more source